PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest they could be used in a wide range of cancers as long as certain mutations are present. PARP drugs work by interfering w...
Original Article: AZ/Merck & Co reveal data supporting PARP drug in prostate cancer